Brainlab, a leading medical technology and software company based in Munich, is planning an initial public offering on the Prime Standard of the Frankfurt Stock Exchange in the coming weeks. This step marks a significant milestone for the company and could be particularly interesting for investors as Brainlab plays a central role in the high-growth MedTech market.
Background and Significance of the Company
Brainlab was founded in 1989 by Stefan Vilsmeier and is now active worldwide with around 2,000 employees. The company develops innovative software solutions for the planning and execution of surgical procedures as well as for radiation therapy in tumors. Brainlab’s technologies are used in about 4,000 healthcare institutions across 120 countries. The precision of the solutions in neurosurgical operations is particularly noteworthy.
Details of the Planned IPO
- Listing: Prime Standard of the Frankfurt Stock Exchange
- Timeline: In the coming weeks
- Capital Increase: Issuance of new shares to raise up to 200 million euros
- Secondary Offering: Sale of existing shares by current shareholders, including founder Stefan Vilsmeier, to ensure sufficient free float
- Use of Funds: Expansion of the business model and strengthening of the balance sheet
Financial Figures and Strategic Direction
In the first half of 2025, Brainlab achieved revenues of around 239 million euros with an operational EBITDA margin of 22.4 percent – an indicator of solid profitability. Speculation about the company’s valuation is around three billion euros, with issuance proceeds potentially reaching half a billion euros. After the IPO, Brainlab plans to further expand its software offerings and strengthen equity to provide flexibility and respond to growth opportunities.
Support for the IPO
The issuance will be supported by a consortium of renowned banks, including Berenberg, Deutsche Bank, Commerzbank, Jefferies, and Unicredit; Evercore is providing advisory support to the company.
Conclusion: Opportunities for Investors
The upcoming IPO positions Brainlab as a promising investment in the dynamic MedTech sector. The combination of an innovative technology platform, international presence, and solid financial foundation makes the company particularly attractive to investors interested in sustainable growth.